Abstract

Treatment of [Pd(PhCN)₂Cl₂] with one equivalent of 2-{1-[2-(1,3-dimethyl-4-nitro-1H-pyrazol-5-yl)hydrazono]methyl} pyridine (PCHP) (3a) or its analogue 2-{1-[2-(1,3-dimethyl-4-nitro-1H-pyrazol-5-yl)hydrazono]ethyl} pyridine (APHP) (3b) produce corresponding pyridine-hydrazone Schiff base coordination complexes [Pd(PCHP)Cl₂] (4a) and [Pd(APHP)Cl₂] (4b), respectively. Compounds 4a,b are characterized by elemental analysis, IR spectroscopy, and ¹H NMR. Attempts to crystalize 4b lead to N–C(sp³)–E pincer palladacycle [Pd(APHP–H)Cl(DMSO)] (5). The molecular structures of 5 in the solid state are determined by single crystal X-ray structure analysis. The X-ray crystal structure of 5 shows the existence of the five-membered metallacycle through the coordination of \(\text{N}-\text{CH}_{2}^{-}\) and pyridine N to the palladium center and the cis arrangement between the metalated nitrogen atom and DMSO. The cytotoxicity of the two ligands and palladium(II) complexes 4a and 5 evaluated against K562 human cancer cell line. The corresponding GI50 (50% growth inhibition) values are compared to the cytotoxicity of cisplatin, under the same experimental conditions, and the results indicate inactive ligands and a superior activity to cisplatin for the complexes.

中文翻译：

---

含吡唑席夫碱配体的新型钯 (II) 络合物：2-{1-[2-(1,3-二甲基-1-1-(1,3-二甲基-1-1-) 钯 (II) 络合物的合成、结构表征和细胞毒性PYRAZOL-5-YL) HydrAZONO]ETHYL} 吡啶 (APHP) 及其类似物 2-{1-[2-(1,3-DIMETHYL-4-NITRO-1H-PYRAZOL-5-YL)Hydrazono]METHYL} 吡啶 ( PCHP)

摘要

用一当量的 2-{1-[2-(1,3-二甲基-4-硝基-1H-吡唑-5-基)肼基]甲基}吡啶 (PCHP)处理 [Pd(PhCN) ₂ Cl ₂ ] ( 3a )或其类似物2-{1-[2-(1,3-二甲基-4-硝基-1H-吡唑-5-基)腙]乙基}吡啶(APHP)( 3b )产生相应的吡啶腙希夫分别为碱配位配合物 [Pd(PCHP)Cl ₂ ] ( 4a ) 和 [Pd(APHP)Cl ₂ ] ( 4b )。化合物4a、b通过元素分析、IR光谱和¹ H NMR表征。尝试结晶4b导致 N–C( sp ³)–E 钳形钯环 [Pd(APHP–H)Cl(DMSO)] ( 5 )。固态下的5的分子结构是通过单晶X射线结构分析确定的。的X射线晶体结构5个通过的协调节目的五元金属环的存在\（\文本{N} - \文本{CH} _ {2} ^ { - } \）和吡啶N-到钯中心和金属化氮原子和 DMSO 之间的顺式排列。两种配体和钯 (II) 配合物4a和5的细胞毒性针对 K562 人癌细胞系进行评估。在相同的实验条件下，将相应的 GI50（50% 生长抑制）值与顺铂的细胞毒性进行比较，结果表明配合物无活性配体和顺铂的优越活性。